Status:
COMPLETED
Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead Sponsor:
University of California, San Diego
Conditions:
Hereditary Hemorrhagic Telangiectasia (HHT)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiec...
Detailed Description
The treatment, regardless of participation in the proposed research, is to bring the patients to the operating room where under general anesthesia the nose is suctioned clean of blood clot, crust and ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults over the age of 18, both male and non-pregnant females capable of making informed consent who have HHT by Curacao criteria and whose nasal bleeding due to HHT is of such a magnitude that it requires medical care.
- Females of childbearing age will be given a pregnancy test as a preliminary measure to ensure that those who become involved are not at risk.
- Generally these patients will have an ESS score of 5 or greater. However on occasion an individual with a score between 2 and 5 but not capable of cleansing their nose adequately to be involved in a Bevacizumab spray treatment may be included.
Exclusion
Key Trial Info
Start Date :
July 22 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 27 2013
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01402531
Start Date
July 22 2010
End Date
July 27 2013
Last Update
December 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Diego
San Diego, California, United States, 92103